Abstract:Abstract Background Multiple missense mutations in Leucine-rich repeat kinase 2 (LRRK2) are associated with familial forms of late onset Parkinson’s disease (PD), the most common age-related movement disorder. The dysfunction of dopamine transmission contributes to PD-related motor symptoms. Interestingly, LRRK2 is more abundant in the dopaminoceptive striatal spiny projection neurons (SPNs) compared to the dopamine-producing nigrostriatal dopaminergic neurons. Aging is the most important risk factor for PD and other neurodegenerative diseases. However, whether LRRK2 modulates the aging of SPNs remains to be determined. Methods We conducted RNA-sequencing (RNA-seq) analyses of striatal tissues isolated from Lrrk2 knockout ( Lrrk2 −/− ) and control ( Lrrk2 +/+ ) mice at 2 and 12 months of age. We examined SPN nuclear DNA damage and epigenetic modifications; SPN nuclear, cell body and dendritic morphology; and the locomotion and motor skill learning of Lrrk2 +/+ and Lrrk2 −/− mice from 2 to 24 months of age. Considering the strength of cell cultures for future mechanistic studies, we also performed preliminary studies in primary cultured SPNs derived from the Lrrk2 +/+ and Lrrk2 −/− mice as well as the PD-related Lrrk2 G2019S and R1441C mutant mice. Results Lrrk2 -deficiency accelerated nuclear hypertrophy and induced dendritic atrophy, soma hypertrophy and nuclear invagination in SPNs during aging. Additionally, increased nuclear DNA damage and abnormal histone methylations were also observed in aged Lrrk2 −/− striatal neurons, together with alterations of molecular pathways involved in regulating neuronal excitability, genome stability and protein homeostasis. Furthermore, both the PD-related Lrrk2 G2019S mutant and LRRK2 kinase inhibitors caused nuclear hypertrophy, while the Lrrk2 R1441C mutant and γ-Aminobutyric acid type A receptor (GABA-AR) inhibitors promoted nuclear invagination in the cultured SPNs. On the other hand, inhibition of neuron excitability prevented the formation of nuclear invagination in the cultured Lrrk2 −/− and R1441C SPNs. Conclusions Our findings support an important physiological function of LRRK2 in maintaining nuclear structure integrity and genomic stability during the normal aging process, suggesting that PD-related LRRK2 mutations may cause the deterioration of neuronal structures through accelerating the aging process.

Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease

LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells

G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice

Rotenone Aggravates PD-like Pathology in A53T Mutant Human Α-Synuclein Transgenic Mice in an Age-Dependent Manner.

LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants

LRRK2 kinase inhibition protects against Parkinson’s disease-associated environmental toxicants

Parkinson’s disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging

Stereotaxical Infusion of Rotenone: A Reliable Rodent Model for Parkinson'S Disease

Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice

Longitudinal Analysis of Fecal Microbiome and Pathologic Processes in a Rotenone Induced Mice Model of Parkinson's Disease.

Aging-related Rotenone-Induced Neurochemical and Behavioral Deficits: Role of SIRT2 and Redox Imbalance, and Neuroprotection by AK-7

Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival

Rotenone-Induced Model of Parkinson's Disease: Beyond Mitochondrial Complex I Inhibition

Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival

Subcutaneous Rotenone Rat Model of Parkinson's Disease: Dose Exploration Study.

Impact of age on the rotenone-induced sporadic Parkinson's disease model using Drosophila melanogaster

The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease

LRRK2 regulates production of reactive oxygen species in cell and animal models of Parkinson's disease

LDN-73794 Attenuated LRRK2-Induced Degeneration in a Drosophila Parkinson’s Disease Model

The R1441C-Lrrk2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner in mice

Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice